{
  "docId": "019de076-c164-739c-925e-e97b24983f20",
  "docSlug": "45699c5d62cd10656fd74cee2718d284",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 45,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "Includes a clinical pipeline chart and a list of recent cell therapy acquisitions/partnerships.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-c164-739c-925e-e97b24983f20/23",
  "deckHref": "/decks/019de076-c164-739c-925e-e97b24983f20",
  "deckJsonHref": "/decks/019de076-c164-739c-925e-e97b24983f20.json",
  "deckAnchorHref": "/decks/019de076-c164-739c-925e-e97b24983f20#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.38,
        "x": 0.57,
        "y": 0.81
      },
      "kind": "callout",
      "text": "Investing in transformational cell therapies with curative potential",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce592450-2819-4995-bdef-2e2ad2bd6be3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.38,
        "x": 0.14,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Innovative immunology portfolio pipeline",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b35b314-54c1-48ca-baa1-f8cfd2855783",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.02,
        "y": 0.96
      },
      "kind": "disclaimer",
      "text": "Gracell acquisition remains subject to customary closing conditions; all clinical development plans mentioned herein subject to deal closure.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0d0a3e1-9a1d-49cb-89cd-42ffbd7219af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.38,
        "x": 0.57,
        "y": 0.25
      },
      "kind": "list",
      "text": "Gracell (Autologous CAR-T), Quell TX (Autologous CAR-Tregs), Cellectis (Allogeneic CAR-T platform)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "313bfd14-4f1f-4466-9c82-3677cadfeeaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Accelerating our ambition in immune-mediated diseases",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f671953d-824e-4a6b-aab6-ea9f24d8d910",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals – R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "975e44e4-b07b-45c4-bc67-93ec989a775c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "50a6d4c2-3c35-42fc-871a-340c38a141a1",
      "evidence": "Pipeline development stages (Phase I-III, Marketed) visualized as horizontal bars.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 26,
      "from": 10,
      "beatId": "43aa94ba-8d07-4798-99cd-6d40ae4b13e2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides an overview of AstraZeneca's financial results and pipeline success",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}